A novel series of quinazoline derivatives 2-8, 10-12 were designed and synthesized. Structures of the newly synthesized compounds were confi rmed by elemental analyses, IR, 1 H and 13 C NMR spectral data. All the newly synthesized compounds were evaluated for in vitro cytotoxic activity against the breast cancer cell line MCF-7. Seven of the novel compounds exhibited higher activity than the reference drug doxorubicin. . In addition, compound 13 showed no activity. Cytotoxic screening of the tested copmpounds off ered an encouraging framework that may lead to the discovery of potent anti-breast cancer activity.
croorganisms (11) (12) (13) . In the light of these facts, and as a continuation of our previous reported work on the synthesis of novel anticancer agents (14-23), we planned to synthesize a novel series of 4-aminoquinazoline derivatives carrying biologically active moieties as analogues to bioactive compounds I-IV, hoping that the new compounds might show signifi cant cytotoxic activity. Anticancer activity of the newly synthesized compounds was evaluated against the human breast cancer cell line MCF-7.
EXPERIMENTAL
Melting points (uncorrected) were determined in an open capillary on a Gallen Kamp melting point apparatus (Sanyo Gallen Kamp, UK). Precoated silica gel plates (Kieselgel 0.25 mm, 60 F254, Merck, Germany) were used for thin layer chromatography. A developing solvent system of chloroform/methanol (8:2) was used; the spots were detected by ultraviolet light and the purity of all synthesized compounds was > 95 %. IR spectra (KBr disc) were recorded using an FT-IR spectrophotometer (Perkin Elmer, USA). 1 H NMR spectra were scanned on a NMR spectrophotometer (Bruker AXS Inc., Switzerland) operating at 500 MHz for 1 H-and 125.76 MHz for 13 C. Chemical shift s are expressed in d-values (ppm) relative to TMS as an internal standard, using DMSO-d 6 as a solvent. Elemental analyses were done on a model 2400 CHNSO analyser (Perkin Elmer, USA). All the values were within ± 0.4 % of the theoretical values. All reagents used were of AR grade. The starting material 4-chloro-2-phenylquinazoline was purchased from Sigma (USA) and was directly used for the preparation of target compounds. nyl)quinazolin-4-amune (7), 2-phenyl-N- (2,4,6-trichlorophenyl) quinazolin-4-amine (8) , N-(4-bro mophenyl)-2-phenylquinazolin-4-amine (9) (25) , N-(2,4-dichlorophenyl)-2-phenylquinazolin-4-amine (10) , N-(adamantan-1-yl)-2-phenylquinazolin-4-amine (11), phenyl (4-(2-phenylquinazolin-4-ylamino) phenyl)methanone (12) , 2-((2-phenylquinazolin-4-yl)amino)anthracene-9,10-dione (13) (26) . General procedure. -A mixture of 4-chloro-2-phenylquinazoline (2.4 g, 0.01 mol) and substituted amine, namely 3-ethylaniline, 4-ethoxyaniline, 3,5-dimethoxyaniline, 3,4,5-trimethoxyaniline, 2-methyl-6-nitroaniline, 2,3,4-trichloroaniline, 2,4,5-trichloroaniline, 2,4,6--trichloroaniline, 4-bromoaniline, 2,4-dibromoaniline, 1-adamantylamine, 4-aminobenzophenone, 2-aminoanthraquinone (0.012 mol) in dimethylformamide (20 mL) was heated under refl ux for 18 h. Aft er cooling, the reaction mixture was poured into ice water. The obtained solid was recrystallized from dioxane to give compounds 1-13, respectively. 
Synthesis of quinazoline derivatives
N-(3-ethylphenyl)-2-phenylquinazolin-4-amine (1) (24), N-(4-ethoxyphenyl)-2-phenylquinazo- lin-4-amine (2), N-(3,5-dimethoxyphenyl)-2-phenylquinazolin-4-amine (3), 2-phenyl-N-(3,4,5-tri- methoxyphenyl)quinazolin-4-amine (4), N-(2-methyl-6-nitrophenyl)-2-phenyl-quinazolin-4-amine (5), 2-phenyl-N-(2,3,4-trichlorophenyl)quinazolin-4-amine (6), 2-phenyl-N-(2,4,5-trichlorophe-
In vitro anti-breast cancer activity
The cytotoxic activity in vitro of the newly synthesized compounds was measured using the sulforhodamine B stain (SRB) assay and the method of Skehan (29) . The human breast cancer cell line MCF-7 (obtained from National Cancer Institute, Cairo, Egypt) was maintained at 37 °C in 5 % CO 2 as sub-confl uent monolayers in 80-mL culture fl asks (Nunclon, Sigma, USA) and were subcultured once or twice weekly in Dulbecco's modifi ed of eagle's medium (Flow, Sigma, USA) supplemented with 5 % heat-inactivated fetal calf serum (FCS) and 1 mmol L -1 L-glutamine (Sigma, USA). During experiments, 50 μg mL -1 gentamicin (Sigma) was added to the culture medium. Passage levels were in the range of 5-20 according to the original receipt. Cells were harvested from exponential phase cultures by trypsinisation, counted and plated in 96-well fl at bott omed microliter plates (Greiner Labortechnik, Germany) (100 μL cell suspension containing 10 4 cells per well). Following plating and a 24-h recovery to allow cells to resume exponential growth, 100 μL of culture medium or culture medium containing the drug was added to the wells. Test compounds were dissolved in DMSO as a 0.1 mol L -1 stock solution (the fi nal concentration of DMSO in culture medium was less than 0.1 %). Diff erent concentrations of each test compound (5, 12, 25 and 50 μmol L -1 ) were obtained by diluting with phosphate buff ered saline (PBS), then added to the cell monolayer. Triplicate wells were prepared for each individual dose. Monolayer cells were incubated with the compound(s) for 48 h at 37 °C and in an atmosphere of 5 % CO 2 . Forty-eight hours aft er drug addition, cells were fi xed with 50 % trichloroacetic acid at 4 °C (50 μL per well) for 1 h, washed with 1 % acetic acid and stained for 30 min with 50 μL of 0.4 % (m/V) SRB dissolved in 1 % acetic acid. Excess unbound dye was removed by four washes with 1 % acetic acid and the att ached stain was recovered with Tris-EDTA buff er. Colour intensity was measured using an enzyme-linked immunosorbent assay ELISA reader. Optical density was read at 510 nm. The relation between the surviving fraction and drug concentration was plott ed to get the survival curve for the breast cancer cell line MCF-7 aft er specifi ed time (29) . The molar concentration required for 50 % inhibition of cell viability (IC 50 ) was preliminarily calculated from the constructed dose-response curve using Prism soft ware (Graphpad, Inc., USA) and the results are given in Table III . RESULTS 
AND DISCUSSION

Chemistry
The compounds were designed with the aim of exploring their anti-breast cancer activity. Thus, 4-aminoquinazoline derivatives 1-13 were synthesized starting from 4-chloro-2-phenylquinazoline as depicted in Schemes 1 and 2. Compounds 1-13 were obtained in good yield via reaction of 4-chloro-2-phenylquinazoline with diff erent amines, as stated in Experimental. Interaction of 4-chloro-2-phenylquinazoline with diff erent amines in dry dimethylformamide yielded the corresponding 4-aminoquinazoline derivatives 1-13. All the synthesized compounds were established on the basis of elemental analyses, IR, 1 H NMR, 13 C NMR and mass spectral data. IR spectra of compounds 1-13 revealed the presence of bands characteristic of NH at 3423 to 3240 cm H NMR spectrum of compound 1 revealed a triplet at 1.2 ppm assigned to CH 3 group and at 2.7 ppm due to CH 2 group. Also, 1 H NMR spectrum of compound 2 showed a triplet at 1.3 ppm for CH 3 , a quartet at 4.0 ppm for CH 2 group. 1 H NMR spectra of compounds 3 and 4 indicated the presence of 2 OCH 3 at 3.8 ppm for compound 3 and 3.7 and 3.8 ppm of 3 OCH 3 groups for compound 4. In addition, 1 H NMR spectrum of compound 5 gave a singlet at 2.2 ppm assigned to CH 3 group. On the other hand, 1 H NMR spectrum of compound 11 revealed the presence of a multiple peer at 1.5-2.3 ppm for adamantane moiety. 13 C NMR spectrum of compound 12 showed a singlet at 195.1 ppm att ributed to C=O group. Scheme 2 In vitro anti-breast cancer activity and SAR Doxorubicin [CAS 23214-92-8], the reference drug used in this study an anthracycline antibiotic is commonly used in the treatment of a wide range of cancers such as acute leukemia's Hodgkin's disease and other lymphomas and cancers of the breast, adrenal cortex, endometrial, lung, ovary, and other sites. The relationship between the cell surviving fraction and drug concentration was plott ed; the response parameters expressed was as IC 50 value, which corresponds to the compound concentration that causes 50 % inhibition of cellular viability (Table III) . Compound 8 with 2,4,6-trichlorophenyl moiety was found to be more active than compound 4 with 3,4,5-trimethoxyphenyl moiety. On the other hand, the chlorine atoms at position 2,4,6 in compound 8 make it more active than when in position 2,3,4 in compound 6 and 2,4,5 in compound 7. The presence of dibromophenyl in compound 10 enhanced the anti-breast cancer activity more than the corre- Table III ) has shown that the activity follows the order 3 > 8 > 4 > 11 > 10 > 12 > 5 > doxorubicin > 1 > 6 > 9 > 2 > 7. These results indicate the possible use of the newly synthesized 4-aminoquinazoline derivatives carrying 3,4-dimethoxyphenyl 3, 2,4,6-trichlorophenyl-(8), 3,4,5-trimethoxyphenyl (4), adamantly (11), 2,4-dibromophenyl (10), phenyl-methanone (12) and 2-methyl-6-nitrophenyl (5) for the treatment of breast tumors.
CONCLUSIONS
In conclusion, we have synthesized several new 4-aminoquinazoline derivatives. The synthesized compounds showed anticancer activity against the human breast cancer cell line MCF-7 higher or comparable activity to that of doxorubicin. We may conclude from the structure-activity relationships that the introduction of 4-amino-3,4-dimethoxyphenyl is associated with enhanced anticancer activity, giving the most potent compound 3 in this study. Combination of 4-aminoquinazoline with 2,4,6-trichlorophenyl moiety in compound 8 increased the activity also. It was found that quinazolin-4-amine derivatives 3, 4, 5, 8, 10, 11 and phenyl-methanone 12 were more potent than the reference drug. In addition, compounds 1, 6, and 9 were nearly as active as doxorubicin, while compounds 2 and 7 were less potent and compound 13 showed no activity.
